"We continue to make excellent progress in the clinical development of our product candidates for Alzheimer's disease and multiple sclerosis. With patient enrollment now complete in the Alzheimer's disease clinical study, we expect to report top-line results after all patients have completed their 6 month follow-up, anticipated to occur toward the end of March 2011. In parallel with this ongoing clinical study, we are working to make Zinthionein commercially available as a prescription medical food," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "We are also encouraged by the continued growth of the client base, net revenues and the expanded testing services offered at Adeona Clinical Laboratory."
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona has the following product candidates in development: a prescription medical food for Alzheimer's disease, and four drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and dry age-related macular degeneration. For more information, please visit Adeona's website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements a
|SOURCE Adeona Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved